Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

NCT02777931 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: NFC-1
DRUG: Placebo

Sponsor

Aevi Genomic Medicine, LLC, a Cerecor company